WuXi AppTec plans $120M integrated biologics solution center
WuXi AppTec, an open-access R&D capability and technology platform company serving the global pharmaceutical, biotechnology and medical device industries, has started construction of a state-of-the-art integrated biologics solution center at the company's headquarters in Shanghai. The company plans to invest a total of $120 million in this dedicated, 250,000-square-foot facility, which will be operational in 2017 and accommodate 800 scientists. The facility will provide integrated solutions from ideas to the clinic for biologics discovery, development and clinical manufacturing on a consolidated campus.
The biologics discovery center will utilize the state-of-the-art OmniRat platform in collaboration with Open Monoclonal Technology, and in-house proprietary phage display libraries to enable global clients to discover conventional mAbs, bi-specific mAbs and antibody-drug conjugates. The biologics development center will utilize WuXi's proprietary CHO cell line platform to develop robust fed-batch and perfusion processes to meet demanding processing needs.
The co-located cGMP clinical manufacturing facilities will support four concurrent campaigns using 3x2000L fed-batch and 2x500L perfusion bioreactors. With this comprehensive platform integrated from discovery through all aspects of development, customers will benefit from the speed, agility, efficiency and quality of WuXi's operations to expedite their global biologics R&D.